GKOS Share Price | Glaukos Corp. Stock Analysis & Recommendation

Q: How big is Glaukos Corp.?

As of Jun 18, Glaukos Corp. has a market capitalization of 5,705.99 million, categorizing it as a Small Cap company.As of Jun 18, the company reported net sales of 404.52 million for the latest four quarters. During the same period, Glaukos Corp. experienced a net profit of -123.69 million.As of Dec 24, the reporting period shows shareholder's funds of 766.93 million and total assets amounting to 1,036.15 million.

Q: What does Glaukos Corp. do?

Overview:Glaukos Corporation is an ophthalmic medical technology company focused on developing and commercializing products and procedures for the treatment of glaucoma, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.Financial Snapshot:- Most recent Net Sales: 107 Million (Quarterly Results - Mar 2025)- Most recent Net Profit: -18 Million (Quarterly Results - Mar 2025)- Market-cap: USD 5,705.99 Million (Small Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: -0.39- Return on Equity: -15.86%- Price to Book: 7.47Contact Details:- Address: 229 Avenida Fabricante, SAN CLEMENTE CA: 92672-7531- Tel: 1 949 3679600- Fax: 1 949 3679984- Website: http://www.glaukos.com/

Q: Who are in the management team of Glaukos Corp.?

As of March 2022, the management team of Glaukos Corp. includes the following individuals:- Dr. William Link, who serves as the Independent Chairman of the Board.- Mr. Thomas Burns, who is the President, Chief Executive Officer, and a Director.- Dr. Gilbert Kliman, who is a Director.- Mr. Mark Foley, who is an Independent Director.- Mr. David Hoffmeister, who is also an Independent Director.- Mr. Marc Stapley, another Independent Director.- Ms. Aimee Weisner, who is an Independent Director.This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Q: Is Glaukos Corp. overvalued or undervalued?

As of 7 May 2020, the valuation grade for Glaukos Corp. moved from attractive to risky, indicating a shift in perception regarding its financial health and market position. The company appears to be overvalued given its high Price to Book Value of 6.96 and negative EV to EBIT and EV to EBITDA ratios of -49.44 and -80.62, respectively. Additionally, the latest ROCE and ROE are concerning at -21.81% and -15.86%, suggesting inefficiencies in generating returns.In comparison to its peers, Glaukos Corp. has a significantly lower P/E ratio of -56.81, while Masimo Corp. shows a P/E of 179.74, and Globus Medical, Inc. presents a more favorable P/E of 18.37, highlighting the disparity in valuation. The company's recent stock performance has been underwhelming, with a year-to-date return of -42.75% compared to the S&P 500's positive return of 12.22%, reinforcing the notion that Glaukos Corp. is currently overvalued in the market.

Q: Is Glaukos Corp. technically bullish or bearish?

As of 31 October 2025, the technical trend for Glaukos Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The RSI shows no signal on the weekly timeframe but is bullish on the monthly, suggesting some underlying strength. However, both the Bollinger Bands and KST are bearish on the weekly and monthly, reinforcing the bearish sentiment. Moving averages are mildly bearish on the daily timeframe.In terms of performance, Glaukos Corp. has underperformed the S&P 500 over the past month and year, with returns of -1.67% and -34.77%, respectively, compared to the S&P 500's 1.92% and 19.89%. This highlights the stock's current weakness relative to the broader market.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

140.75 k

Shareholding (Dec 2025)

FII

14.66%

Held by 167 FIIs

DII

20.35%

Held by 73 DIIs

Promoter

0.61%

How big is Glaukos Corp.?

22-Jun-2025

As of Jun 18, Glaukos Corp. has a market capitalization of $5.71 billion, with net sales of $404.52 million and a net profit of -$123.69 million over the latest four quarters. Shareholder's funds are $766.93 million, and total assets amount to $1.04 billion.

View full answer

What does Glaukos Corp. do?

22-Jun-2025

Glaukos Corporation is an ophthalmic medical technology company specializing in glaucoma treatments, with recent net sales of $107 million and a market cap of approximately $5.7 billion. The company is currently operating at a loss, with a net profit of -$18 million.

View full answer

Who are in the management team of Glaukos Corp.?

22-Jun-2025

As of March 2022, Glaukos Corp.'s management team includes Dr. William Link (Independent Chairman), Mr. Thomas Burns (President and CEO), and several independent directors: Dr. Gilbert Kliman, Mr. Mark Foley, Mr. David Hoffmeister, Mr. Marc Stapley, and Ms. Aimee Weisner. This team provides governance and strategic direction for the company.

View full answer

Is Glaukos Corp. overvalued or undervalued?

20-Sep-2025

As of May 7, 2020, Glaukos Corp. is considered overvalued and risky due to its high Price to Book Value of 6.96, negative EV to EBIT and EV to EBITDA ratios, low ROCE and ROE, and poor stock performance compared to its peers and the S&P 500.

View full answer

Is Glaukos Corp. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Glaukos Corp. is in a mildly bearish trend, with mixed technical indicators and underperformance compared to the S&P 500, showing returns of -1.67% over the past month and -34.77% over the past year.

View full answer

Compare Glaukos Corp. with Similar Stocks

Inari Medical, Inc.Neogen Corp.Globus Medical, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Operating Profit of 17.44%, the company declared Very Positive results in Jun 25

OPERATING CASH FLOW(Y) Highest at USD -20.62 MM
NET PROFIT(HY) Higher at USD -37.8 MM
ROCE(HY) Highest at -12.98%

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 6,911 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.42

Return on Equity

-10.09%

Price to Book

10.53

Revenue and Profits:

Net Sales:

143 Million

(Quarterly Results - Dec 2025)

Net Profit:

-134 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-13.03%

6 Months

20.15%

1 Year

-3.18%

2 Years

15.73%

3 Years

100.24%

4 Years

85.18%

5 Years

11.24%

Glaukos Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

17.67%

EBIT Growth (5y)

6.46%

EBIT to Interest (avg)

-5.91

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.39

Sales to Capital Employed (avg)

0.52

Tax Ratio

0.59%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.96

EV to EBIT

-44.32

EV to EBITDA

-76.86

EV to Capital Employed

8.74

EV to Sales

9.90

PEG Ratio

Dividend Yield

ROCE (Latest)

-19.72%

ROE (Latest)

-12.13%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 97 Schemes (64.31%)

Foreign Institutions

Held by 167 Foreign Institutions (14.66%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 7.19% vs 7.57% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -725.31% vs 17.77% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "143.10",
          "val2": "133.50",
          "chgp": "7.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.80",
          "val2": "-6.20",
          "chgp": "-122.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "1.20",
          "chgp": "-8.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-112.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-133.70",
          "val2": "-16.20",
          "chgp": "-725.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-188.70%",
          "val2": "-122.60%",
          "chgp": "-6.61%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 32.31% vs 21.86% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -28.21% vs -8.69% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "507.40",
          "val2": "383.50",
          "chgp": "32.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-44.40",
          "val2": "-68.20",
          "chgp": "34.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.60",
          "val2": "28.10",
          "chgp": "-83.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-112.90",
          "val2": "-14.20",
          "chgp": "-695.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-187.70",
          "val2": "-146.40",
          "chgp": "-28.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-170.90%",
          "val2": "-282.00%",
          "chgp": "11.11%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

143.10

133.50

7.19%

Operating Profit (PBDIT) excl Other Income

-13.80

-6.20

-122.58%

Interest

1.10

1.20

-8.33%

Exceptional Items

-112.90

0.00

Consolidate Net Profit

-133.70

-16.20

-725.31%

Operating Profit Margin (Excl OI)

-188.70%

-122.60%

-6.61%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 7.19% vs 7.57% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -725.31% vs 17.77% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

507.40

383.50

32.31%

Operating Profit (PBDIT) excl Other Income

-44.40

-68.20

34.90%

Interest

4.60

28.10

-83.63%

Exceptional Items

-112.90

-14.20

-695.07%

Consolidate Net Profit

-187.70

-146.40

-28.21%

Operating Profit Margin (Excl OI)

-170.90%

-282.00%

11.11%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 32.31% vs 21.86% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -28.21% vs -8.69% in Dec 2024

All Annual Results

Company CV

About Glaukos Corp.

Glaukos Corp.

Pharmaceuticals & Biotechnology

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.

Company Coordinates

Company Details

229 Avenida Fabricante , SAN CLEMENTE CA : 92672-7531

Tel: 1 949 3679600

http://www.glaukos.com/

Registrar Details